Invasive cervical cancer (ICC) is one of the most common
cancers affecting women in the United States. Approximately
12,170 cases of ICC and 4,220 deaths are expected
in 2012 [1]. While its incidence and mortality rates appear
modest compared to other cancers, ICC remains a high
priority for several reasons. First, with screening via
Papanicolaou (Pap) tests, nearly all ICC cases can be
prevented. Further, the Pap test is a well-established, low
cost, and generally widely available screening test. Finally,
the burden of ICC mortality falls most heavily on certain
traditionally underserved populations [2].